nasdaq:ardm
|
17261
|
Aug 19th, 2019 12:00AM
|
Insmed Corporation
|
597
|
52.00
|
Open
|
Biotechnology
|
Aug 18th, 2019 10:08PM
|
Aug 18th, 2019 10:08PM
|
We are Fulfilling Unmet Needs in Pulmonary Medicine.
Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease.
Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following:
• Continued development of proprietary respiratory disease therapies
• Pursue regulatory pathways that reduce the time, costs and risks associated with product development
• Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing
• Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States
• Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise
|
Open
|
|
|
|
|
|
US
|
|
|
Aradigm
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:ardm
|
17261
|
Aug 18th, 2019 12:00AM
|
Insmed Corporation
|
597
|
52.00
|
Open
|
Biotechnology
|
Aug 17th, 2019 10:08PM
|
Aug 17th, 2019 10:08PM
|
We are Fulfilling Unmet Needs in Pulmonary Medicine.
Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease.
Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following:
• Continued development of proprietary respiratory disease therapies
• Pursue regulatory pathways that reduce the time, costs and risks associated with product development
• Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing
• Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States
• Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise
|
Open
|
|
|
|
|
|
US
|
|
|
Aradigm
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:ardm
|
17261
|
Aug 17th, 2019 12:00AM
|
Insmed Corporation
|
596
|
53.00
|
Open
|
Biotechnology
|
Aug 16th, 2019 10:08PM
|
Aug 16th, 2019 10:08PM
|
We are Fulfilling Unmet Needs in Pulmonary Medicine.
Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease.
Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following:
• Continued development of proprietary respiratory disease therapies
• Pursue regulatory pathways that reduce the time, costs and risks associated with product development
• Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing
• Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States
• Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise
|
Open
|
|
|
|
|
|
US
|
|
|
Aradigm
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:ardm
|
17261
|
Aug 16th, 2019 12:00AM
|
Insmed Corporation
|
596
|
52.00
|
Open
|
Biotechnology
|
Aug 16th, 2019 10:47AM
|
Aug 16th, 2019 10:47AM
|
We are Fulfilling Unmet Needs in Pulmonary Medicine.
Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease.
Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following:
• Continued development of proprietary respiratory disease therapies
• Pursue regulatory pathways that reduce the time, costs and risks associated with product development
• Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing
• Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States
• Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise
|
Open
|
|
|
|
|
|
US
|
|
|
Aradigm
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:ardm
|
17261
|
Aug 15th, 2019 12:00AM
|
Insmed Corporation
|
595
|
52.00
|
Open
|
Biotechnology
|
Aug 15th, 2019 11:43AM
|
Aug 15th, 2019 11:43AM
|
We are Fulfilling Unmet Needs in Pulmonary Medicine.
Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease.
Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following:
• Continued development of proprietary respiratory disease therapies
• Pursue regulatory pathways that reduce the time, costs and risks associated with product development
• Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing
• Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States
• Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise
|
Open
|
|
|
|
|
|
US
|
|
|
Aradigm
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:ardm
|
17261
|
Aug 14th, 2019 12:00AM
|
Insmed Corporation
|
595
|
52.00
|
Open
|
Biotechnology
|
Aug 14th, 2019 11:36AM
|
Aug 14th, 2019 11:36AM
|
We are Fulfilling Unmet Needs in Pulmonary Medicine.
Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease.
Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following:
• Continued development of proprietary respiratory disease therapies
• Pursue regulatory pathways that reduce the time, costs and risks associated with product development
• Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing
• Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States
• Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise
|
Open
|
|
|
|
|
|
US
|
|
|
Aradigm
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:ardm
|
17261
|
Aug 13th, 2019 12:00AM
|
Insmed Corporation
|
593
|
53.00
|
Open
|
Biotechnology
|
Aug 12th, 2019 10:08PM
|
Aug 12th, 2019 10:08PM
|
We are Fulfilling Unmet Needs in Pulmonary Medicine.
Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease.
Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following:
• Continued development of proprietary respiratory disease therapies
• Pursue regulatory pathways that reduce the time, costs and risks associated with product development
• Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing
• Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States
• Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise
|
Open
|
|
|
|
|
|
US
|
|
|
Aradigm
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:ardm
|
17261
|
Aug 12th, 2019 12:00AM
|
Insmed Corporation
|
592
|
52.00
|
Open
|
Biotechnology
|
Aug 12th, 2019 09:27AM
|
Aug 12th, 2019 09:27AM
|
We are Fulfilling Unmet Needs in Pulmonary Medicine.
Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease.
Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following:
• Continued development of proprietary respiratory disease therapies
• Pursue regulatory pathways that reduce the time, costs and risks associated with product development
• Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing
• Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States
• Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise
|
Open
|
|
|
|
|
|
US
|
|
|
Aradigm
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:ardm
|
17261
|
Aug 11th, 2019 12:00AM
|
Insmed Corporation
|
592
|
52.00
|
Open
|
Biotechnology
|
Aug 10th, 2019 10:09PM
|
Aug 10th, 2019 10:09PM
|
We are Fulfilling Unmet Needs in Pulmonary Medicine.
Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease.
Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following:
• Continued development of proprietary respiratory disease therapies
• Pursue regulatory pathways that reduce the time, costs and risks associated with product development
• Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing
• Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States
• Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise
|
Open
|
|
|
|
|
|
US
|
|
|
Aradigm
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:ardm
|
17261
|
Aug 10th, 2019 12:00AM
|
Insmed Corporation
|
592
|
53.00
|
Open
|
Biotechnology
|
Aug 9th, 2019 10:09PM
|
Aug 9th, 2019 10:09PM
|
We are Fulfilling Unmet Needs in Pulmonary Medicine.
Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease.
Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following:
• Continued development of proprietary respiratory disease therapies
• Pursue regulatory pathways that reduce the time, costs and risks associated with product development
• Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing
• Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States
• Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise
|
Open
|
|
|
|
|
|
US
|
|
|
Aradigm
|
|
Pharmaceuticals & Biotechnology
|